Celio, Luigi
Cortinovis, Diego
Cogoni, Alessio Aligi
Cavanna, Luigi
Martelli, Olga
Carnio, Simona
Collovà, Elena
Bertolini, Federica
Petrelli, Fausto
Cassano, Alessandra
Chiari, Rita
Zanelli, Francesca
Pisconti, Salvatore
Vittimberga, Isabella
Letizia, Antonietta
Misino, Andrea
Gernone, Angela
Bonizzoni, Erminio
Pilotto, Sara
De Placido, Sabino
Bria, Emilio
Article History
Received: 22 April 2022
Accepted: 18 August 2022
First Online: 24 August 2022
Declarations
:
: The phase 3 study was done in compliance with the Declaration of Helsinki and the study protocol was approved by the institutional review boards and the Ethics Committees of each participating institution. All patients included in the phase 3 study provided written informed consent.
: Not applicable.
: LCe received consulting fees from Berlin-Chemie, Italfarmaco SpA and Kyowa Kirin. RC has declared speaker’s fee - advisory boards from Astrazeneca, Roche, BMS, MSD, Pfizer, and Takeda. EBo received consulting fees from Helsinn. SP received speakers’ fees from MSD, Astra-Zeneca, BMS, Boehringer Ingelheim and Roche. EBr received speakers’ and travels’ fees from MSD, AstraZeneca, Celgene, Pfizer, Helsinn, Eli-Lilly, BMS, Novartis and Roche, as well as institutional research grants from AstraZeneca and Roche. All remaining authors have declared no conflicts of interest.